Post-Market Surveillance

Regulatory oversight doesn't end when a vaccine receives approval. Manufacturers are legally required to conduct ongoing safety surveillance, and regulators actively monitor vaccines throughout their market life. This page documents the post-market requirements and enforcement mechanisms.

Manufacturer Requirements

• Adverse event reporting: Must report all serious adverse events to FDA within 15 days
• Periodic Safety Update Reports (PSURs): Regular reports on benefit-risk balance
• Post-marketing studies: May be required as condition of approval
• Label changes: Must update labeling with new safety information
• Manufacturing compliance: Ongoing adherence to cGMP standards

Regulatory Surveillance Systems

Regulators operate multiple surveillance systems:

• VAERS (US): Passive reporting system for adverse events
• VSD (US): Active surveillance linking vaccine records to health outcomes
• BEST (US): FDA's active surveillance using claims databases
• EudraVigilance (EU): EU-wide adverse event database
• Yellow Card (UK): UK MHRA reporting system

Enforcement Mechanisms

Regulators have several tools to address safety concerns:

• Label changes: Add warnings, contraindications, or adverse reactions
• Risk Evaluation and Mitigation Strategies (REMS): Required safety measures
• Suspension: Temporarily halt distribution
• Revocation: Withdraw marketing authorization
• Recalls: Remove problematic batches or products

Key Examples

Post-market surveillance has led to important regulatory actions:

• Rotavirus vaccines: Early signals of intussusception led to reformulation
• 1999 rotavirus withdrawal: RotaShield withdrawn due to intussusception
• COVID-19 vaccines: Myocarditis signals detected and investigated
• Janssen vaccine: GBS warning added based on post-market data

Sources & Citations

• FDA: Safety Availability
• CDC: Vaccine Safety Monitoring